Daniel S. Lorrain

CIK: 0001861550

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)22 (64.7%)

Position reduction

Option Exercises (M)8 (23.5%)

Derivative conversions

Awards (A)4 (11.8%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CTNM

Contineum Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (34 total)

CTNM
Contineum Therapeutics, Inc.
Jul 9, 2026
Sale(S)
Direct
25 shares at avg. $16.00$400
CTNM
Contineum Therapeutics, Inc.
Jul 9, 2026
Exercise(M)
Direct
25 shares at avg. $1.01$25.25
CTNM
Contineum Therapeutics, Inc.
Jul 8, 2026
Sale(S)
Direct
1K shares at avg. $16.00$16K
CTNM
Contineum Therapeutics, Inc.
Jul 8, 2026
Exercise(M)
Direct
1K shares at avg. $1.01$1K
CTNM
Contineum Therapeutics, Inc.
Jul 1, 2026
Sale(S)
Direct
2.5K shares at avg. $16.24$41K
CTNM
Contineum Therapeutics, Inc.
Jul 1, 2026
Exercise(M)
Direct
4.2K shares at avg. $1.01$4K
CTNM
Contineum Therapeutics, Inc.
Jul 1, 2026
Sale(S)
Direct
5.9K shares at avg. $15.67$92K
CTNM
Contineum Therapeutics, Inc.
Jun 30, 2026
Exercise(M)
Direct
28.8K shares at avg. $1.01$29K
CTNM
Contineum Therapeutics, Inc.
Jun 30, 2026
Sale(S)
Direct
28.8K shares at avg. $16.04$462K
CTNM
Contineum Therapeutics, Inc.
Jun 1, 2026
Sale(S)
Direct
4.2K shares at avg. $13.16$55K
CTNM
Contineum Therapeutics, Inc.
May 1, 2026
Sale(S)
Direct
3.9K shares at avg. $13.06$51K
CTNM
Contineum Therapeutics, Inc.
May 1, 2026
Sale(S)
Direct
300 shares at avg. $13.84$4K
CTNM
Contineum Therapeutics, Inc.
Apr 6, 2026
Sale(S)
Direct
4.2K shares at avg. $13.43$56K
CTNM
Contineum Therapeutics, Inc.
Mar 2, 2026
Sale(S)
Direct
4.2K shares at avg. $15.01$63K
CTNM
Contineum Therapeutics, Inc.
Feb 25, 2026
Sale(S)
Direct
3.8K shares at avg. $16.01$61K
CTNM
Contineum Therapeutics, Inc.
Feb 25, 2026
Exercise(M)
Direct
3.8K shares at avg. $1.01$4K
CTNM
Contineum Therapeutics, Inc.
Feb 24, 2026
Exercise(M)
Direct
4.3K shares at avg. $1.01$4K
CTNM
Contineum Therapeutics, Inc.
Feb 24, 2026
Sale(S)
Direct
4.3K shares at avg. $16.03$69K
CTNM
Contineum Therapeutics, Inc.
Feb 19, 2026
Exercise(M)
Direct
100 shares at avg. $1.01$101
CTNM
Contineum Therapeutics, Inc.
Feb 19, 2026
Sale(S)
Direct
100 shares at avg. $16.00$2K
CTNM
Contineum Therapeutics, Inc.
Feb 11, 2026
Exercise(M)
Direct
400 shares at avg. $1.01$404
CTNM
Contineum Therapeutics, Inc.
Feb 11, 2026
Sale(S)
Direct
400 shares at avg. $16.00$6K
CTNM
Contineum Therapeutics, Inc.
Feb 3, 2026
Sale(S)
Direct
1.2K shares at avg. $15.25$18K
CTNM
Contineum Therapeutics, Inc.
Feb 3, 2026
Sale(S)
Direct
3K shares at avg. $14.82$44K
CTNM
Contineum Therapeutics, Inc.
Jan 30, 2026
Award(A)
Stock Option (right to buy)
Indirect
6.5K shares-

		Type	Shares	Price		Ownership
Jul 9, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	25	$16.00	$400	Direct
Jul 9, 2026	CTNM Contineum Therapeutics, Inc.	Exercise(M)	25	$1.01	$25	Direct
Jul 8, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	1,015	$16.00	$16,240	Direct
Jul 8, 2026	CTNM Contineum Therapeutics, Inc.	Exercise(M)	1,015	$1.01	$1,025	Direct
Jul 1, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	2,501	$16.24	$40,608	Direct
Jul 1, 2026	CTNM Contineum Therapeutics, Inc.	Exercise(M)	4,183	$1.01	$4,225	Direct
Jul 1, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	5,852	$15.67	$91,682	Direct
Jun 30, 2026	CTNM Contineum Therapeutics, Inc.	Exercise(M)	28,826	$1.01	$29,114	Direct
Jun 30, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	28,826	$16.04	$462,288	Direct
Jun 1, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	4,170	$13.16	$54,862	Direct
May 1, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	3,870	$13.06	$50,542	Direct
May 1, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	300	$13.84	$4,152	Direct
Apr 6, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	4,170	$13.43	$56,014	Direct
Mar 2, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	4,170	$15.01	$62,585	Direct
Feb 25, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	3,824	$16.01	$61,228	Direct
Feb 25, 2026	CTNM Contineum Therapeutics, Inc.	Exercise(M)	3,824	$1.01	$3,862	Direct
Feb 24, 2026	CTNM Contineum Therapeutics, Inc.	Exercise(M)	4,300	$1.01	$4,343	Direct
Feb 24, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	4,300	$16.03	$68,936	Direct
Feb 19, 2026	CTNM Contineum Therapeutics, Inc.	Exercise(M)	100	$1.01	$101	Direct
Feb 19, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	100	$16.00	$1,600	Direct
Feb 11, 2026	CTNM Contineum Therapeutics, Inc.	Exercise(M)	400	$1.01	$404	Direct
Feb 11, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	400	$16.00	$6,400	Direct
Feb 3, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	1,170	$15.25	$17,837	Direct
Feb 3, 2026	CTNM Contineum Therapeutics, Inc.	Sale(S)	3,000	$14.82	$44,469	Direct
Jan 30, 2026	CTNM Contineum Therapeutics, Inc.	Award(A) Stock Option (right to buy)	6,500	-	-	Indirect

1-25 of 34 transactions

About Lorrain Daniel S.

Lorrain Daniel S. (SEC CIK 0001861550) files insider reports with the SEC as Chief Scientific Officer of Contineum Therapeutics, Inc. (CTNM).

Signal8 holds 16 ownership filings by Lorrain Daniel S., all Form 4s, filed between Nov 20, 2024 and Jul 10, 2026. Those filings report 34 transactions, from Nov 18, 2024 to Jul 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lorrain Daniel S.'s filings is in SAN DIEGO, CA.

Recent filings by Lorrain Daniel S.

Jul 9, 2026: Open-market sale of CTNM shares (Form 4, code S).
Jul 9, 2026: Option exercise of CTNM shares (Form 4, code M).
Jul 8, 2026: Open-market sale of CTNM shares (Form 4, code S).
Jul 8, 2026: Option exercise of CTNM shares (Form 4, code M).
Jul 1, 2026: Open-market sale of CTNM shares (Form 4, code S).

Other insiders filing for Contineum Therapeutics, Inc. (CTNM)

Stengone Carmine N., CEO and President
Watkins Tim, CMO & Head of Development
Miralles Gines Diego, Director
Lyons-Williams Lori, Director
Ware Olivia C, Director
Schimmelpennink Evert B., Director

How to read Form 4 transaction codes